EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV

Kyle Ring iD, Alexa Elias iD, Megan Devonald iD, Melanie Smuk iD, Chloe Orkin iD

HIV Medicine · 2025

DOI: 10.1111/hiv.70057 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift HIV Medicine, 2025. Verfasst von Kyle Ring und 4 weiteren Autor:innen. Beteiligte Einrichtung: SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Pyridones, Drug Resistance, Viral. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy. The optimal regimen is uncertain.

Methods

We synthesized evidence from PubMed, EMBASE, Cochrane and conference abstract databases through 18 November 2024, to identify observational cohort studies (OCS) that reported on VF events in virally suppressed individuals who switched to LA‐I CAB+RPV. We extracted data on VF, resistance‐associated mutations (RAMs) at VF, post‐VF regimen choice and re‐suppression. We assessed the risk of bias using a modified Downs and Black tool.

Results

VF definitions differed considerably among OCS, with 172 individuals experiencing VF across 79 cohorts that included 13 899 individuals. Twenty‐eight cohorts ( n = 7987) reported genotypic information at VF. Out of the 80 VF events with genotypic information available at the time of the VF event, NNRTI mutations were identified in 45 cases, INIs in 40 cases, and dual‐class resistance in 33 cases. Notably, 28 VF events were not accompanied by resistance. Post‐VF regimen choices were reported for 92 VF events. Regimens used were protease inhibitor (PI)‐based, oral INI‐based and some physicians continued LA‐I CAB+RPV post‐VF. Re‐suppression occurred in 87.8% (65/74) of VF events in which it was described.

Conclusions

In OCS, VF was a very uncommon occurrence and comparable with clinical trials. However, when it did occur, it was frequently accompanied by resistance. Post‐VF regimens used to achieve suppression varied, including LA‐I CAB+RPV maintenance and were highly successful.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsPyridonesDrug Resistance, ViralAnti-HIV AgentsHumansObservational Studies as TopicTreatment FailureHIV-1Viral LoadCohort StudiesDelayed-Action PreparationsDiketopiperazines

Stichwörter der Autor:innen

cabotegravir rilpivirineclinical practicelong‐acting ARTresistancere‐suppressionvirological failure

Substanzen

RilpivirinePyridonescabotegravirAnti-HIV AgentsDelayed-Action PreparationsDiketopiperazines

Autor:innen und Institutionen

  • SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Barts Health NHS Trust, London, UK.

ORCID-Profile: Kyle Ring, Alexa Elias, Megan Devonald, Melanie Smuk, Chloe Orkin

Förderung

  • ViiV Healthcare

Zitieren

APA

Ring, K., Elias, A., Devonald, M., Smuk, M., & Orkin, C. (2025). Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV. HIV Medicine. https://doi.org/10.1111/hiv.70057

Vancouver

Ring K, Elias A, Devonald M, Smuk M, Orkin C. Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV. HIV Medicine. 2025. doi:10.1111/hiv.70057

BibTeX
@article{Ring2025,
  author = {Ring, Kyle and Elias, Alexa and Devonald, Megan and Smuk, Melanie and Orkin, Chloe},
  title = {Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70057}
}
Kostenlos starten →